Anavex Life Sciences Corp. (NASDAQ:AVXL) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 most shorted penny stocks to buy. More than 500% upside potential ...

Anavex Life Sciences stock recently jumped in response to phase 3 clinical trial results for an Alzheimer's disease candidate. Anavex described its results as successful, but industry experts were far ...

Can a biotech stock that's down by about 40% in the last month have any chance of rallying to multiply in value by a factor of five over the next two years? Prospective investors looking for a big ...

Anavex is set to release its financial results for the second fiscal quarter on May 13, 2025, providing transparency to shareholders and stakeholders. The conference call scheduled after the results ...

Anavex announced that the primary and secondary endpoints were met in a phase 2b/3 study targeting early Alzheimer's disease. However, some observers are questioning the quality of Anavex's data.

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome. What sets Anavex ...

Anavex Life Sciences ( (AVXL) ) has issued an update.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amyloid ...

Anavex Life Sciences slipped in after-hours trading on Monday after the company said it plans to raise as much as $300 million by selling shares. The stock closed at $11.48 on Monday, up 3.3% for the ...